GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., particularly those 60 and older.

GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once again. GSK now expects to generate more than 40 billion pound ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to infants and young children, RSV poses an even greater risk to older adults ...

Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

These findings have been implemented by GSK and Pfizer to utilize the pre-F RSV protein as their immunogen for vaccine research. The availability of high purity, conformationally verified proteins ...

Analysts welcomed the strong earnings, while UBS's Jo Walton said in a note that the 18-month buyback would not impact GSK's ability to fund small deals. Walmsley's bet on blockbuster RSV vaccine ...

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show ...